BMRN - Biomarin Pharmaceutical - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09061G1013

Enzyme Replacement Therapies, Proteins, Enzymes, Injections, Medications

BioMarin Pharmaceutical Inc. is a pioneering biotech company that develops and commercializes innovative therapies for people suffering from rare and life-threatening diseases. Their mission is to make a meaningful difference in the lives of patients and families affected by these debilitating conditions.

The company's portfolio of commercial products is impressive, with a range of treatments for various rare diseases. For instance, Vimizim is an enzyme replacement therapy that helps treat mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder. Naglazyme, on the other hand, is a recombinant form of N-acetylgalactosamine 4-sulfatase that helps patients with MPS VI. Kuvan, another proprietary treatment, is a synthetic oral form of 6R-BH4 that helps manage phenylketonuria (PKU), an inherited metabolic disease.

In addition to these treatments, BioMarin's commercial products also include Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme that reduces blood Phe concentrations in patients with PKU. Brineura is another treatment that helps patients with ceroid lipofuscinosis type 2, a form of Batten disease. Voxzogo, a once-daily injection, is used to treat achondroplasia, a genetic disorder that affects bone growth. Aldurazyme, a purified protein, is designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.

BioMarin is also working on developing innovative treatments, such as Roctavian, an adeno-associated virus vector that has the potential to revolutionize the treatment of severe hemophilia A. The company's commitment to research and development is unwavering, and they have established partnerships with other biotech companies, including Sarepta Therapeutics, Ares Trading S.A., and Catalyst Pharmaceutical Partners, Inc.

With a strong presence in the United States, Europe, Latin America, and internationally, BioMarin serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers. Headquartered in San Rafael, California, the company was incorporated in 1996 and has been making a significant impact in the lives of patients and families affected by rare diseases.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for BMRN - Biomarin Pharmaceutical  - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for BMRN - Biomarin Pharmaceutical  - Stock & Dividends

BMRN Stock Overview

Market Cap in USD 15,908m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1999-07-23

BMRN Stock Ratings

Growth 5y 4.04
Fundamental 34.6
Dividend -
Rel. Performance vs Sector -2.01
Analysts 4.14/5
Fair Price Momentum 77.30 USD
Fair Price DCF 22.66 USD

BMRN Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

BMRN Growth Ratios

Growth 12m -0.99%
Growth Correlation 12m -29%
Growth Correlation 3m -9%
CAGR 5y 0.24%
CAGR/Mean DD 5y 0.01
Sharpe Ratio 12m -0.23
Alpha vs SP500 12m -20.64
Beta vs SP500 5y weekly 0.68
ValueRay RSI 76.25
Volatility GJR Garch 1y 27.62%
Price / SMA 50 4.87%
Price / SMA 200 -2.15%
Current Volume 1274k
Average Volume 20d 3323k

External Links for BMRN Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of BMRN stocks?
As of July 14, 2024, the stock is trading at USD 85.02 with a total of 1,274,029 shares traded.
Over the past week, the price has changed by +4.38%, over one month by +0.56%, over three months by -7.81% and over the past year by -1.90%.
What are the forecast for BMRN stock price target?
According to ValueRays Forecast Model, BMRN Biomarin Pharmaceutical will be worth about 85.1 in July 2025. The stock is currently trading at 85.02. This means that the stock has a potential upside of +0.04%.
Issuer Forecast Upside
Wallstreet Target Price 108 27.1
Analysts Target Price 117 37.6
ValueRay Target Price 85.1 0.04